<?xml version="1.0" encoding="UTF-8"?><rss xmlns:dc="http://purl.org/dc/elements/1.1/" xmlns:content="http://purl.org/rss/1.0/modules/content/" xmlns:atom="http://www.w3.org/2005/Atom" version="2.0"><channel><title><![CDATA[Resistance to immune checkpoint inhibitors remains a major barrier in cancer care, often driven by patients relapsing despite initial responses.]]></title><description><![CDATA[<p>Resistance to immune checkpoint inhibitors remains a major barrier in cancer care, often driven by patients relapsing despite initial responses. To understand this dynamic, researchers developed a mathematical model focusing on age-associated senescence in CD8+ T cells, where aging immune cells secrete vascular growth factors that support tum...</p><p><a href="https://www.bioscience.com.pk/en/subject/medicine/senolytic-drug-reduces-cancer-resistance-to-pd-l1-blockade" rel="nofollow noopener"><span>https://www.</span><span>bioscience.com.pk/en/subject/m</span><span>edicine/senolytic-drug-reduces-cancer-resistance-to-pd-l1-blockade</span></a></p><p><a href="https://mastodon.social/tags/Medicine" rel="tag">#<span>Medicine</span></a> <a href="https://mastodon.social/tags/MedicalScience" rel="tag">#<span>MedicalScience</span></a> <a href="https://mastodon.social/tags/Health" rel="tag">#<span>Health</span></a></p>]]></description><link>https://postcall.pub/topic/3f759a67-7a9b-4fa8-95f4-2f139a51453f/resistance-to-immune-checkpoint-inhibitors-remains-a-major-barrier-in-cancer-care-often-driven-by-patients-relapsing-despite-initial-responses.</link><generator>RSS for Node</generator><lastBuildDate>Sun, 22 Nov 2026 22:25:58 GMT</lastBuildDate><atom:link href="https://postcall.pub/topic/3f759a67-7a9b-4fa8-95f4-2f139a51453f.rss" rel="self" type="application/rss+xml"/><pubDate>Sun, 22 Nov 2026 08:04:54 GMT</pubDate><ttl>60</ttl></channel></rss>